| abstract |
The present invention provides use of borrelidin, an isomer, or pharmaceutically acceptable salt thereof, for the treatment of an inflammatory disorder. The invention further relates to a pharmaceutical composition comprising borrelidin, an isomer, or pharmaceutically acceptable salt thereof, for use in the treatment of an inflammatory disorder. The invention also relates to a method for the treatment of an inflammatory disorder by administering a therapeutically effective amount of borrelidin, an isomer, or pharmaceutically acceptable salt thereof to a subject in need thereof. The said inflammatory disorder may be mediated by elevated levels of one or more inflammatory cytokines selected from Tumor Necrosis Factor-alpha (TNF-α) and interleukins (IL-1 β, IL-6, IL-8) or increased expression of one or more cell adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1 ), vascular-cell adhesion molecule 1 (VCAM-1 ) and E-Selectin or a combination thereof. |